New pancreatic drug approved

What's happened

The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.

What's behind the headline?

Why this matters now

The FDA has approved the first oral therapy that convincingly extends survival in heavily pretreated metastatic pancreatic cancer. That overturns decades of failed attempts to drug the KRAS pathway and turns a laboratory advance into a readily prescribed medicine.

What the approval will change

• Clinicians will shift treatment discussions from palliative chemotherapy-only options to an oral targeted alternative for patients with KRAS-driven disease who have exhausted prior lines of therapy. This will increase demand for rapid biomarker testing and specialist involvement.
• Expanded-access programmes and early authorisations have already exposed more than 2,000 patients to the drug; insurers and health systems will now face urgent pricing and coverage decisions given the roughly $39,800 monthly list price.
• Drugmakers who have KRAS-targeting programmes will accelerate trials across lung, colorectal and other cancers where KRAS mutations drive tumours, increasing trial enrolment and competition.

Risks and limits

• The trial was company-funded and enrolled patients with metastatic, previously treated disease; daraxonrasib is not a cure and the median benefit remains measured in months, not years.
• Side effects — including skin toxicity, mucositis and gastrointestinal issues — are common and roughly 44% of patients experienced severe adverse events, so onco-dermatology and toxicity management will scale up.
• Access will depend on insurers and assistance programmes; patients outside the US will face variable availability and pricing.

What to watch next

• Payer coverage decisions and patient out-of-pocket costs will determine how rapidly the drug reaches wider use.
• Results from ongoing trials testing the drug in other KRAS-driven cancers will determine whether this approval sparks a broader therapeutic class expansion.

Bottom line

This approval will change clinical conversations and drug development priorities; it will force fast decisions on testing, toxicity management and who will pay for an expensive but clearly beneficial oral therapy.

How we got here

Pancreatic cancer has been historically lethal and resistant to targeted drugs. Researchers have been racing to block mutated KRAS proteins; daraxonrasib uses a molecular-glue approach and has been fast-tracked after trial results showed substantially longer survival and fewer severe side effects than standard chemotherapy.

Our analysis

The New York Times Business and BBC Business have provided comprehensive clinical and regulatory context: the Times reports that daraxonrasib "has electrified cancer specialists and patients" and notes the drug is taken as two pills daily and that Wall Street expects high prices (New York Times Business, Aug. 27 and Aug. 26). BBC Business summarised the FDA rationale and trial outcomes, noting a median survival of 13.2 months versus about 6.6–6.7 months on chemotherapy and quoted the FDA saying the drug provided a "critical new option" (BBC Business, Aug. 26). Reuters/ CNBC and AP supplied concise regulatory and trial details, reporting that the approval covers adults with metastatic pancreatic cancer who have had prior therapy or cannot take combination chemotherapy and that the trial enrolled 500 patients (CNBC, AP News, Aug. 26). Pricing and patient experiences have driven public attention. The Times of Israel and France 24 both reported the company price of about $39,800 per 30-day supply and described patient reports of improved quality of life and reduced chemo-related symptoms (Times of Israel, France 24, Aug. 27). Individual accounts and Bloomberg profiles (Aug. 26–28) illustrated rapid symptomatic improvements under early-access programmes. Taken together, these sources show consistent clinical trial results and regulatory urgency; differences lie mainly in emphasis — US outlets foreground regulatory speed, trial metrics and commercial forecasts, while patient-focused pieces highlight quality-of-life gains and toxicity. All sources underline that the drug is a breakthrough but not a cure.

Go deeper

• How will insurers and Medicare decide to cover Rasonque and what will patients pay out of pocket?
• Will oncologists start routine KRAS subtyping earlier to identify candidates for daraxonrasib?
• When will trial results appear testing daraxonrasib in lung or colorectal cancers?

More on these topics

• KRAS - Protein-coding gene in the species Homo sapiens

  The KRAS gene provides instructions for making a protein called K-Ras, part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus.

• American Cancer Society - Voluntary organization

  The American Cancer Society is a nationwide voluntary health organization dedicated to eliminating cancer. Established in 1913, the society is organized into six geographical regions of both medical and lay volunteers operating in more than 250 Regional o

• United States - Country in North America

  The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.

• California - US State

  California is a state in the Pacific Region of the United States. With 39.5 million residents across a total area of about 163,696 square miles, California is the most populous U.S. state and the third-largest by area, and is also the world's thirty-fourt

• Ben Sasse - United States Senator

  Benjamin Eric Sasse is an American politician, author, professor, and academic administrator who serves as the junior United States Senator from Nebraska, a seat he was first elected to in 2014. Sasse is a member of the Republican Party.

• 60 Minutes - American television program

  60 Minutes is an American television news magazine broadcast on the CBS television network. Debuting in 1968, the program was created by Don Hewitt, who chose to set it apart from other news programs by using a unique style of reporter-centered investigat

• New York Post - Newspaper

  The New York Post is a daily newspaper in New York City. The Post also operates NYPost.com, the celebrity gossip site PageSix.com and the entertainment site Decider.com. The modern version of the paper is published in tabloid format.

• Nebraska - US State

  Nebraska is a state that lies both in the Great Plains and in the Midwestern United States. It is bordered by South Dakota to the north; Iowa to the east and Missouri to the southeast, both across the Missouri River; Kansas to the south; Colorado to the s

• CBS Broadcasting Inc. - Television broadcasting company

  CBS is an American commercial broadcast television and radio network that is the flagship property of the CBS Entertainment Group division of ViacomCBS.

• Redwood City - City in California

  Redwood City is a city on the San Francisco Peninsula in Northern California's Bay Area, approximately 27 miles south of San Francisco, and 24 miles northwest of San Jose.

• Colorectal cancer - Cancer of the colon or rectum

  Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine), in which uncontrolled growth of colon cells that can invade/spread to other parts of the body takes place. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, abdominal pain and fatigue. Most colorectal cancers are due to lifestyle factors and genetic disorders. Risk factors include diet, obesity, smoking, and lack of physical activity. Dietary factors that increase the risk include red meat, processed meat, and alcohol. Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous. Colorectal cancer may be diagnosed by obtaining a sample of the colon during a sigmoidoscopy or colonoscopy. This is then followed by medical imaging to determine...

• Howard Hughes Medical Institute - Foundation

  The Howard Hughes Medical Institute (HHMI) is an American non-profit medical research organization based in Chevy Chase, Maryland. It was founded in 1953, by Howard Hughes who was an American business magnate, investor, record-setting pilot, engineer...

• City of Hope - Wikimedia disambiguation page

  City of Hope may refer to: City of Hope (1991 film), a film taking place in fictitious Hudson City, New Jersey City of Hope (1948 film), a French drama film City of Hope National Medical Center, a cancer center in Duarte, California City of Hope (charity), the medical center's charity City of Hope, a song by Journey from Eclipse, 2011

• Pfizer - Pharmaceutical company

  Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City. It is one of the world's largest pharmaceutical companies.

• Robert Wood Johnson Foundation - Health care company

  The Robert Wood Johnson Foundation is the United States' largest philanthropy focused solely on health; it is based in Princeton, New Jersey. The foundation's goal, through the use of grants, is "to improve the health and health care of all Americans." Th

• British Heart Foundation - Charity

  The British Heart Foundation is a charity organisation in the United Kingdom. It funds research to beat heartbreak from heart and circulatory diseases and their risk factors.